Literature DB >> 25206745

A non-invasive, rapid method to genotype late-onset Alzheimer's disease-related apolipoprotein E gene polymorphisms.

Li Yi1, Ting Wu1, Wenyuan Luo1, Wen Zhou2, Jun Wu1.   

Abstract

The apolipoprotein E gene ε4 allele is considered a negative factor for neural regeneration in late-onset Alzheimer's disease cases. The aim of this study was to establish a non-invasive, rapid method to genotype apolipoprotein E gene polymorphisms. Genomic DNA from mouth swab specimens was extracted using magnetic nanoparticles, and genotyping was performed by real-time PCR using TaqMan-BHQ probes. Genotyping accuracy was validated by DNA sequencing. Our results demonstrate 100% correlation to DNA sequencing, indicating reliability of our protocol. Thus, the method we have developed for apolipoprotein E genotyping is accurate and reliable, and also suitable for genotyping large samples, which may help determine the role of the apolipoprotein E ε4 allele in neural regeneration in late-onset Alzheimer's disease cases.

Entities:  

Keywords:  DNA sequencing; allele; apolipoprotein E gene; late-onset Alzheimer's disease; nerve regeneration; neural regeneration; neurodegeneration; real-time PCR; risk factor

Year:  2014        PMID: 25206745      PMCID: PMC4146311          DOI: 10.4103/1673-5374.125332

Source DB:  PubMed          Journal:  Neural Regen Res        ISSN: 1673-5374            Impact factor:   5.135


Introduction

Alzheimer's disease is the most common form of dementia related to aging, and is a progressive neurodegenerative disease affecting millions of people worldwide[12]. Clinically, Alzheimer's disease presents with anterograde episodic memory impairments, intellectual disturbances, language problems, and decline in other cognitive domains[34]. Neuropathologically, Alzheimer's disease is characterized by extracellular senile plaques (formed by aggregates of cleaved β-amyloid (Aβ) protein), intracellular neurofibrillary tangles (mainly composed of hyperphosphorylated tau protein), and neuronal loss[5678]. Alzheimer's disease is typically divided into early-onset and late-onset forms. Early-onset Alzheimer's disease is rare, whereas late-onset Alzheimer's disease (with an onset age of over 65) accounts for approximately 95% of all Alzheimer's disease cases[91011]. Early-onset Alzheimer's disease can be identified by genetic mutations in amyloid precursor protein, presenilin-1, and presenilin-2. Late-onset Alzheimer's disease lacks obvious genetic mutations[121314], however many studies have shown that apolipoprotein E (APOE) ε4 gene is the most important known genetic risk factor[1516]. Thus, is APOE ε4 a genetic maker of late-onset Alzheimer's disease? APOE is polymorphic, and encodes a 34.2 kDa glycosylated protein, APOE[17]. APOE is located on chromosome 19q13.2, and comprised of four exons and three introns, covering 3,597 bp[1819]. The two APOE single nucleotide polymorphisms associated with Alzheimer's disease are rs429358 and rs7412. The three common variants resulting from these polymorphisms are ε2 (rs429358, T; rs7412, T), ε3 (rs429358, T; rs7412, C) and ε4 (rs429358, C; rs7412, C). In humans, these variants result in three homozygous (ε2/ε2,ε3/ε3, and ε4/ε4), and three heterozygous (ε2/ε3, ε2/ε4, and ε3/ε4) phenotypes. APOE ε2, ε3, and ε4 determine the three major protein isoforms of APOE, specifically, APOE2, E3, and E4[202122]. On the mature APOE polypeptide chain, APOE2 has cysteine residues at positions 112 and 158, APOE3 has a cysteine and arginine residue at positions 112 and 158, respectively, and APOE4 has arginine residues at both sites. Despite differing by only one or two amino acids at residues 112 and/or 158, the structure and function of APOE protein isoforms are profoundly altered[232425]. Carriers of one or two APOE ε4 alleles have a three- or eleven-fold, respectively, increased risk for late-onset Alzheimer's disease[26]. As neuronal loss is one of the pathological characteristics of late-onset Alzheimer's disease, in recent years emphasis has been placed on neural regeneration research. The APOE ε4 allele is considered a negative factor for neural regeneration[2728]. APOE4 exhibits greater neurotoxicity than APOE2 and APOE3, and affects neural regeneration mainly by generating neurotoxic fragments that lead to pathological mitochondrial dysfunction and cytoskeletal collapse[29]. However, the exact mechanism whereby the APOE ε4 allele inhibits neural regeneration in late-onset Alzheimer's disease is not completely understood[3031]. APOE genotyping is crucial to APOE polymorphism analysis. Peripheral venous blood is the conventional tissue source for APOE polymorphism analysis[3233]. Blood yields high-quality genomic DNA and can meet various research purposes. However, because of invasiveness, taking blood samples decreases compliance among the elderly, especially neuropsychiatric patients[343536]. Moreover, blood specimens often need cold storage, thereby increasing the cost. In contrast, buccal mucosa sampling through mouth swabs is non-invasive and generates high-quality genomic DNA for single nucleotide polymorphism genotyping. Specimens can be stored at room temperature[37383940]. Ilveskoski et al.[41] reported successful APOE genotyping from buccal swabs using the restriction enzyme HhaI, although the process was labor- and time-consuming (taking a total of ten hours). Magnetic nanoparticles are novel materials for genomic DNA isolation in molecular biology. Wang and Su[42] have shown magnetic nanoparticles effectively and rapidly enrich trace amounts of DNA. Real-time PCR is a high-throughput method for single nucleotide polymorphism analysis[33]. Thus, we aimed to establish a method for genomic DNA extraction from mouth swab specimens using magnetic nanoparticles coupled with APOE genotyping by real-time PCR using TaqMan-BHQ probes.

Results

Rapid APOE genotyping by real-time PCR

Real-time PCR amplification took 50 minutes. The whole procedure was operated in closed tubes. After amplification, genotypes were automatically read by the Endpoint Genotyping module. Representative rs429358 and rs7412 genotyping results are shown (Figure 1).
Figure 1

Results of rs429358 (A) and rs7412 (B) genotypings using the Roche LightCycler 480II system.

NTC: Negative template control.

Results of rs429358 (A) and rs7412 (B) genotypings using the Roche LightCycler 480II system. NTC: Negative template control.

APOE genotyping by DNA sequencing

DNA sequencing was performed by the Beijing Genomics Institute in China, using the ABI3730 DNA Sequencer (Applied Biosystems). Typical results are presented (Figures 2, 3).
Figure 2

Screenshots of rs429358 genotyping obtained by DNA sequencing.

(A) rs429358 T/T; (B) rs429358 C/T; (C) rs429358 C/C. Arrows show polymorphic sites.

Figure 3

Screenshots of rs7412 genotyping obtained by DNA sequencing.

(A) rs7412 C/C; (B) rs7412 C/T; (C) rs7412 T/T. Arrows show polymorphic sites.

Screenshots of rs429358 genotyping obtained by DNA sequencing. (A) rs429358 T/T; (B) rs429358 C/T; (C) rs429358 C/C. Arrows show polymorphic sites. Screenshots of rs7412 genotyping obtained by DNA sequencing. (A) rs7412 C/C; (B) rs7412 C/T; (C) rs7412 T/T. Arrows show polymorphic sites.

Genotype analysis of the APOE ε4 allele, a risk factor for late-onset Alzheimer's disease

APOE genotyping by real-time PCR using TaqMan-BHQ probes, showed 100% correlation with DNA sequencing results, demonstrating reliability of our protocol. Genotype and allele frequencies, and Hardy-Weinberg equilibrium tests are summarized (Table 1). Both cases and controls were in Hardy-Weinberg equilibrium (P > 0.05), indicating our subjects were genetically randomly selected. APOE genotype distributions between cases and controls were significantly different (P = 0.004). The APOE ε4 allele was associated with high risk (P = 0.001; odds ratio (OR) 3.958, 95% confidence interval (CI) 1.681–9.319) for developing late-onset Alzheimer's disease, supporting the APOE ε4 allele as a risk factor for late-onset Alzheimer's disease[16] (Tables 2, 3).
Table 1

Genotype and allele frequencies of rs429358 and rs7412 and Hardy-Weinberg equilibrium (HWE) tests in cases and controls

Table 2

APOE phenotype distribution in cases and controls

Table 3

APOE genotype distribution in cases and controls

Genotype and allele frequencies of rs429358 and rs7412 and Hardy-Weinberg equilibrium (HWE) tests in cases and controls APOE phenotype distribution in cases and controls APOE genotype distribution in cases and controls

Discussion

The APOE ε4 allele is well known to play an important role in the pathological processes of late-onset Alzheimer's disease, in particular, Aβ generation or deposition, neurofibrillary tangle formation, lipid homeostasis, neuronal survival, and intracellular signal transduction[434445]. In the central nervous system, APOE is considered important for repairing and maintaining myelin and neuronal membranes during growth and injury[4647]. Of the three isoforms, APOE4 is the least stable, and less effective at accomplishing these functions. The APOE ε4 isoform shows higher affinity for binding Aβ and stabilizing amyloid fibrils, thereby enhancing Aβ accumulation in plaques. Late-onset Alzheimer's disease patients with one or two APOE ε4 alleles have more senile plaques and Aβ deposition[48495051]. APOE plays a fundamental role in regulating transport of cholesterol and phospholipids among cells[52]. APOE ε4 genotypes are associated with less APOE protein in plasma. Plasma low density lipoprotein levels are higher in APOE ε4 allele carriers[53545556]. Cholinergic signal transduction is impaired in the majority of late-onset Alzheimer's disease patients. Among these patients, APOE ε4 allele carriers have greater deficits in cholinergic activity in the hippocampus and cortex, and fewer cholinergic neurons[4344]. APOE ε4 allele effects on neural regeneration in late-onset Alzheimer's disease cases are complex and can be summarized as follows: (1) APOE4 inhibits neurite outgrowth; (2) APOE4 leads to mitochondrial dysfunction including membrane potential alterations, mitochondrial motility reductions, and mitochondrial respiratory enzymes dysfunction; (3) APOE4 impairs the cytoskeleton and causes tau hyperphosphorylation; (4) APOE4 inhibits synaptogenesis, increases Aβ and lysosomal leakage, and causes neuronal apoptosis; and (5) animal experiments show APOE4 memory and learning impairments in mice[2957]. Much remains to be determined to explain APOE ε4 allele effects on neural regeneration in late-onset Alzheimer's disease cases. Thus, APOE genotyping of large samples is indispensable. Besides compliance, efficiency and cost of sample collection need to be considered when screening large samples. Thomson and colleagues[58] recommended buccal cells as the first choice for PCR DNA analysis. In our study, 107 mouth swab specimens were collected. The process of specimen collection was non-invasive and no discomfort was reported. The procedure of collecting mouth swab specimens was easy to manage, with no specialized facilities or even skilled collection staff required. It took only several seconds to collect one mouth swab specimen. Compared with blood specimens, the cost of mouth swab specimen collection was reduced. According to the manufacturer, one sterile mouth swab costs < 0.1 dollar. No anticoagulant was needed and specimens could be stored at room temperature for more than two weeks. We used magnetic nanoparticles to extract genomic DNA from the mouth swab samples. Compared with traditional human genomic DNA extraction kits, magnetic nanoparticles have several advantages. They are highly efficient at enriching genomic DNA because of their large specific surface area, which can notably enlarge the reaction interface. Due to their superparamagnetic effects, magnetic nanoparticles are easy to use, enabling them to be moved and isolated with external magnetic fields supplied by magnetic stands or common magnetic irons[59]. Furthermore, magnetic nanoparticles degenerate easily, supporting environmental protection. In our assay, the time spent in extracting genomic DNA from one mouth swab specimen was just one hour. PCR-restriction fragment length polymorphism analysis is the most common method applied to genotype APOE polymorphisms[6061]. However, PCR-restriction fragment length polymorphism analysis is not an effective method, as it requires a number of reaction steps (i.e., PCR, overnight enzyme digestion, electrophoresis, and ultraviolet irradiation). Moreover, it is prone to insufficient restriction enzyme digestion resulting in inaccurate results. DNA sequencing is the most accurate method for APOE genotyping, but it is labor-consuming and requires expensive detection equipment that small laboratories can often not afford. Real-time PCR is a time- and labor-saving, high-throughput protocol for single nucleotide polymorphism analysis. To date, SYBR Green, hybridization probes, and TaqMan-MGB probes have been used in real-time PCR for APOE genotyping[3233]. SYBR Green, a double stranded DNA-fluorescent dye, is inexpensive, however, it is not specific enough and tends to be affected by primer-dimer formation[61]. Hybridization and TaqMan-MGB probes are highly specific, although high price restricts their application. TaqMan-BHQ is a specific fluorescence probe that is cheaper than hybridization or TaqMan-MGB probes. TaqMan-BHQ probe application shows an increasing trend in recent years, especially in small laboratories. Our assay demonstrates that TaqMan-BHQ probes are accurate and reliable for APOE genotyping, with confirmation of our results by PCR with DNA sequencing. Genotyping with TaqMan-BHQ probes requires no post-PCR sample handling, reducing the chance of sample contamination and mix-up. We used negative template controls for real-time PCR amplification, and observed no contamination. Samples were rechecked on different days, with comparable results, showing good assay reproducibility. A single real-time PCR reaction took approximately 50 minutes, and the Roche LightCycler 480 II system has the potential to run 384 reactions at one time. In conclusion, our method for APOE genotyping is non-invasive, fast, and economical, with the potential for high-throughput application. It is suitable for screening APOE ε4 allele carriers among large samples, which may help elucidate the influence of the APOE ε4 allele in late-onset Alzheimer's disease cases.

Subjects and Methods

Design

A novel test method for clinical research.

Time and setting

Experiments were performed in the Central Laboratory of Peking University Shenzhen Hospital, China from July 2011 to April 2012.

Subjects

A total of 50 late-onset Alzheimer's disease cases (mean age 74.2 ± 5.8 years, 24 males and 26 females), diagnosed according to criteria of the National Institute of Neurological and Communicative Disorders and Stroke, and the Alzheimer's Diseases and Relative Disorders Associations[62], and 57 age-matched healthy controls (mean age 72.98 ± 4.76 years, 29 males and 28 females), were recruited from the in- and out-patient departments of the Center of Health Examination, Peking University Shenzhen Hospital. All participants were from the Han Chinese population. Written informed consent was obtained from subjects or surrogates. The study was performed in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Peking University Shenzhen Hospital, China.

Methods

Preparation of mouth swab specimens

Sterile mouth swabs (Jiangsu KangJian Medical Apparatus, Jiangyan, Jiangsu Province, China) were used to collect cheek epithelial cells from subjects. The inside of both cheeks was rubbed and swabs were swirled five times. Tips of mouth swab specimens were cut into 1.5 mL microcentrifuge tubes and stored at room temperature until DNA extraction.

Human genomic DNA extraction

The Magnetic Nanoparticles DNA Extraction Kit (Wawasye Nanotech, Wuhan, Hubei Province, China), including magnetic nanoparticles, and lysis, binding, washing, and elution buffers, was used. Lysis buffer (200 µL) was added to mouth swab specimens and vortexed for seconds. Tubes were centrifuged briefly at 12,000 × g at room temperature, and then incubated at 80°C for 30 minutes. Tubes were again briefly centrifuged at 12,000 × g and supernatants transferred to clean microcentrifuge tubes. Magnetic nanoparticles (20 µL) were added and mixed by inversion 20 times. Mixtures were then incubated at room temperature for 10 minutes. Tubes were again briefly centrifuged and supernatants discarded. Tubes were placed into a magnetic stand to preserve magnetic nanoparticles when discarding supernatants. Washing buffer (100 µL) was added and mixed by inversion 20 times. Supernatants were discarded using the magnetic stand. The washing procedure was repeated, and magnetic nanoparticles permitted to air dry for five minutes. Following this, elution buffer (50 µL) was added and incubated at 70°C for 10 minutes. After brief centrifugation, supernatants (including genomic DNA) were transferred to clean microcentrifuge tubes and stored at −20°C until use.

APOE genotyping by real-time PCR

Primer and probe sequences for rs429358 genotyping were designed by Shanghai Genecore Biotechnologies (Genecore, Shanghai, China), and were: forward primer 5′-ACC TCG CCG CGG TAC TG-3′, reverse primer 5′-GGG CAC GGC TGT CCA A-3′; TaqMan probe pair 5′-FAM-CGG CCG CAC ACG TCC TCC-BHQ-3′, 5′-HEX-CGG CCG CGC ACG TCC T-BHQ-3′. For rs7412 genotyping, sequences according to Koch et al.[33] were used: forward primer 5′-CGC GGC CCT GTT CCA-3′, reverse primer 5′-CTC CGC GAT GCC GAT G-3′; TaqMan probe pair 5′-FAM-ACT GCC AGG CGC TTC TGC AGG-BHQ-3′, 5′-HEX-CAC TGC CAG GCA CTT CTG CAG GT-BHQ-3′. All primers and probes were synthesized and purified by Genecore. Real-time PCR amplification reactions for rs429358 and rs7412 genotyping were performed using the Roche LightCycler 480II system (Roche Diagnostics, Basel, Switzerland). Reactions contained 5 µL of 2 × premix Ex Taq (TaKaRa, Dalian, Liaoning Province, China), 2.5 µmol/L of each primer, 1.25 µmol/L of each TaqMan probe, and 2 µL of genomic DNA. Sterile water was added to a final volume of 10 µL. Negative template controls, using sterile water instead of genomic DNA, were included in every amplification. Cycling parameters were: an initial denaturation at 95°C for 30 seconds, followed by 40 cycles of denaturation at 95°C for 5 seconds, annealing and extension at 60°C for 31 seconds, and finally cooling to 4°C. After amplification, genotypes were automatically determined by the Roche LightCycler 480 service software, equipped with the Endpoint Genotyping module.

DNA sequencing

DNA sequencing was performed to validate APOE genotyping obtained by real-time PCR. The primer pair sequences (5′-GGG CAC GGC TGT CCA A-3′ and 5′-CGC GGC CCT GTT CCA-3′) used, produced a 300 bp fragment encompassing rs429358 and rs7412, and were designed and synthesized by Genecore. PCR amplification reactions were performed using the ABI 2720 Thermal Cycler (Applied Biosystems, CA, USA). PCR reaction volumes were 25 µL, and included 12.5 µL of 2 × premix Ex Taq (TaKaRa), 5 µmol/L of each primer, 2 µL of genomic DNA, and 9.5 µL of sterile water. Appropriate negative controls were included in each run. Amplification conditions were: an initial denaturation at 95°C for 30 seconds, followed by 40 cycles of denaturation at 95°C for 30 seconds, annealing at 60°C for 30 seconds, and extension at 72°C for 18 seconds. Southern blots were performed to verify amplification of the expected 300 bp APOE products. PCR products (5 µL) were mixed with 6 × loading buffer (1 µL) (TaKaRa) and electrophoresed on 2% agarose gels. Amplicons were measured using the DL1000 molecular mass marker (TaKaRa). PCR products of 300 bp were sent to Beijing Genomics Institute (Shenzhen, Guangdong Province, China) for DNA sequencing.

Statistical analysis

Genotype distributions and allele frequencies of rs429358 and rs7412 were obtained by direct counting. To determine if genotype distributions were in Hardy-Weinberg equilibrium, tests were performed using R[63]. Other analyses were performed using SPSS 13.0 software (SPSS, Chicago, IL, USA). Genotype frequencies between two groups, were compared using chi-square tests and assessment of APOE ε4 allele risk for late-onset Alzheimer's disease determined. P ≤ 0.05 was considered statistically significant.
  61 in total

Review 1.  Cardiovascular risk factors and Alzheimer's disease.

Authors:  José A Luchsinger; Richard Mayeux
Journal:  Curr Atheroscler Rep       Date:  2004-07       Impact factor: 5.113

2.  Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease.

Authors:  Michael Ewers; Zhenyu Zhong; Katharina Bürger; Anders Wallin; Kaj Blennow; Stefan J Teipel; Yong Shen; Harald Hampel
Journal:  Brain       Date:  2008-03-11       Impact factor: 13.501

3.  Global prevalence of dementia: a Delphi consensus study.

Authors:  Cleusa P Ferri; Martin Prince; Carol Brayne; Henry Brodaty; Laura Fratiglioni; Mary Ganguli; Kathleen Hall; Kazuo Hasegawa; Hugh Hendrie; Yueqin Huang; Anthony Jorm; Colin Mathers; Paulo R Menezes; Elizabeth Rimmer; Marcia Scazufca
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

Review 4.  Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease.

Authors:  Robert W Mahley; Karl H Weisgraber; Yadong Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

Review 5.  Apolipoprotein e sets the stage: response to injury triggers neuropathology.

Authors:  Robert W Mahley; Yadong Huang
Journal:  Neuron       Date:  2012-12-06       Impact factor: 17.173

6.  Apolipoprotein E allele epsilon 4 is linked to increased deposition of the amyloid beta-peptide (A-beta) in cases with or without Alzheimer's disease.

Authors:  C Berr; J J Hauw; P Delaère; C Duyckaerts; P Amouyel
Journal:  Neurosci Lett       Date:  1994-09-12       Impact factor: 3.046

7.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

8.  Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia.

Authors:  Federica Agosta; Keith A Vossel; Bruce L Miller; Raffaella Migliaccio; Stephen J Bonasera; Massimo Filippi; Adam L Boxer; Anna Karydas; Katherine L Possin; Maria Luisa Gorno-Tempini
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-22       Impact factor: 11.205

Review 9.  Apolipoprotein E: a major piece in the Alzheimer's disease puzzle.

Authors:  A Cedazo-Mínguez; R F Cowburn
Journal:  J Cell Mol Med       Date:  2001 Jul-Sep       Impact factor: 5.310

Review 10.  Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease.

Authors:  Adam Kline
Journal:  Alzheimers Res Ther       Date:  2012-08-27       Impact factor: 6.982

View more
  10 in total

1.  Cardiovascular Pharmacogenomics and Cognitive Function in Patients with Schizophrenia.

Authors:  Kristen M Ward; A Zarina Kraal; Stephanie A Flowers; Vicki L Ellingrod
Journal:  Pharmacotherapy       Date:  2017-08-02       Impact factor: 4.705

2.  Matrix metalloproteinase-degraded type I collagen is associated with APOE/TOMM40 variants and preclinical dementia.

Authors:  Man-Hung Eric Tang; Joseph P M Blair; Cecilie Liv Bager; Anne-Christine Bay-Jensen; Kim Henriksen; Claus Christiansen; Morten Asser Karsdal
Journal:  Neurol Genet       Date:  2020-09-10

3.  A rapid and cost-effective method for genotyping apolipoprotein E gene polymorphism.

Authors:  Li Zhong; Yong-Zhuang Xie; Tian-Tian Cao; Zongqi Wang; Tingting Wang; Xinxiu Li; Rui-Chi Shen; Huaxi Xu; Guojun Bu; Xiao-Fen Chen
Journal:  Mol Neurodegener       Date:  2016-01-12       Impact factor: 14.195

4.  Apolipoprotein E polymorphisms increase the risk of post-stroke depression.

Authors:  Xue-Bin Li; Jie Wang; An-Ding Xu; Jian-Min Huang; Lan-Qing Meng; Rui-Ya Huang; Jun-Li Wang
Journal:  Neural Regen Res       Date:  2016-11       Impact factor: 5.135

5.  The effect of an interactive cycling training on cognitive functioning in older adults with mild dementia: study protocol for a randomized controlled trial.

Authors:  E G A Karssemeijer; W J R Bossers; J A Aaronson; R P C Kessels; M G M Olde Rikkert
Journal:  BMC Geriatr       Date:  2017-03-21       Impact factor: 3.921

6.  The quest for synergy between physical exercise and cognitive stimulation via exergaming in people with dementia: a randomized controlled trial.

Authors:  Esther G A Karssemeijer; Justine A Aaronson; Willem J R Bossers; Rogier Donders; Marcel G M Olde Rikkert; Roy P C Kessels
Journal:  Alzheimers Res Ther       Date:  2019-01-05       Impact factor: 6.982

7.  Training Computers to See the Built Environment Related to Physical Activity: Detection of Microscale Walkability Features Using Computer Vision.

Authors:  Marc A Adams; Christine B Phillips; Akshar Patel; Ariane Middel
Journal:  Int J Environ Res Public Health       Date:  2022-04-09       Impact factor: 3.390

8.  Prognosis of Alzheimer's Disease Using Quantitative Mass Spectrometry of Human Blood Plasma Proteins and Machine Learning.

Authors:  Alexey S Kononikhin; Natalia V Zakharova; Savva D Semenov; Anna E Bugrova; Alexander G Brzhozovskiy; Maria I Indeykina; Yana B Fedorova; Igor V Kolykhalov; Polina A Strelnikova; Anna Yu Ikonnikova; Dmitry A Gryadunov; Svetlana I Gavrilova; Evgeny N Nikolaev
Journal:  Int J Mol Sci       Date:  2022-07-18       Impact factor: 6.208

9.  Apolipoprotein E genotyping using PCR-GoldMag lateral flow assay and its clinical applications.

Authors:  Ting Lian; Wenli Hui; Xianying Li; Chao Zhang; Juanli Zhu; Rui Li; Yinsheng Wan; Yali Cui
Journal:  Mol Med Rep       Date:  2016-09-23       Impact factor: 2.952

10.  Identifying diagnosis-specific genotype-phenotype associations via joint multitask sparse canonical correlation analysis and classification.

Authors:  Lei Du; Fang Liu; Kefei Liu; Xiaohui Yao; Shannon L Risacher; Junwei Han; Lei Guo; Andrew J Saykin; Li Shen
Journal:  Bioinformatics       Date:  2020-07-01       Impact factor: 6.937

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.